The Development Process and Characteristics of Antibodies in Antibody-drug Conjugate

More than 100 years ago, Paul Ehrlich, the father of immunology, first proposed the concept of magic bullets, i.e., the concept of selectively delivering toxic drugs to target cells while avoiding damage to normal cells in the human body. ADCs, as a new type of anticancer drug, are formed by coupling small molecule cytotoxins with monoclonal antibody molecules through linker molecules. As a new type of anticancer drug, ADC couples a small molecule cytotoxin with a monoclonal antibody molecule through a linker molecule, and the drug formed by the combination is targeted and lethal, leading the new era of targeted cancer therapy. In this review, the current development and outlook of ADCs is comprehensively reviewed, ADCs and ongoing R&D pipelines in the global and Chinese markets are analyzed,Various ADC platforms and technologies pertinent to distinct pharmaceutical and biotech firms are emphasized, alongside an exploration of emerging technologies, potential advancements for next-generation ADCs, and avenues for clinical research.